Literature DB >> 6407502

A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine.

P Dick, E Ferrero.   

Abstract

1 We report the results of a comparative clinical trial of a new antidepressant drug fluvoxamine (a specific re-uptake inhibitor of 5-hydroxytryptamine (5-HT)) with chlorimipramine. Thirty-two patients with mixed depression received one or the other drug at the same daily dosage of 150 mg. 2 In both drug groups there was an overall clinically significant improvement for all items on the Hamilton Rating Scale for Depression (67% improvement in both groups). 3 In the chlorimipramine group there were more digestive symptoms and anticholinergic effects; the difference with the fluvoxamine group approached statistical significance. 4 No clinically important effects of either treatment were observed on heart-rate or blood pressure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407502      PMCID: PMC1427654          DOI: 10.1111/j.1365-2125.1983.tb02132.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

2.  Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  V Claassen; J E Davies; G Hertting; P Placheta
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

3.  Diagnostic criteria for use in psychiatric research.

Authors:  J P Feighner; E Robins; S B Guze; R A Woodruff; G Winokur; R Munoz
Journal:  Arch Gen Psychiatry       Date:  1972-01
  3 in total
  7 in total

Review 1.  Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; A Ward
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

Review 2.  Fluvoxamine: clinical trials and clinical use.

Authors:  C P Freeman
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 3.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2.

Authors:  Mizuho Sekine; Ryosuke Arakawa; Hiroshi Ito; Masaki Okumura; Takeshi Sasaki; Hidehiko Takahashi; Harumasa Takano; Yoshiro Okubo; Christer Halldin; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

5.  Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial.

Authors:  T Bougerol; C Uchida; J P Gachoud; M Köhler; H Mikkelsen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 6.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 7.  Comparative efficacy of antidepressants.

Authors:  S Kasper; J Fuger; H J Möller
Journal:  Drugs       Date:  1992       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.